BDBM50507492 Loxo-195::Selitrectinib::US10966985, Compound 33-B
SMILES C[C@@H]1CCc2ncc(F)cc2[C@H]2CCCN2c2ccn3ncc(C(=O)N1)c3n2
InChI Key InChIKey=OEBIHOVSAMBXIB-SJKOYZFVSA-N
Data 44 IC50
Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB
Found 8 hits for monomerid = 50507492
Affinity DataIC50: 2.70nMAssay Description:The potency of a compound inhibiting wild type and exemplary mutant ROS1 kinases was determined using CisBio's HTRF Kinease-TK assay technology. ...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase ROS [D2033N](Homo sapiens (Human))
Array Biopharma
US Patent
Array Biopharma
US Patent
Affinity DataIC50: 3.60nMAssay Description:The potency of a compound inhibiting wild type and exemplary mutant ROS1 kinases was determined using CisBio's HTRF Kinease-TK assay technology. ...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase ROS [G2032R](Homo sapiens (Human))
Array Biopharma
US Patent
Array Biopharma
US Patent
Affinity DataIC50: 0.5nMAssay Description:The potency of a compound inhibiting wild type and exemplary mutant ROS1 kinases was determined using CisBio's HTRF Kinease-TK assay technology. ...More data for this Ligand-Target Pair
Affinity DataIC50: 2.70nMAssay Description:The potency of a compound inhibiting wild type and exemplary mutant ROS1 kinases was determined using CisBio's HTRF Kinease-TK assay technology. ...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase ROS [G2032R](Homo sapiens (Human))
Array Biopharma
US Patent
Array Biopharma
US Patent
Affinity DataIC50: 20.4nMAssay Description:The potency of a compound inhibiting wild type and exemplary mutant ROS1 kinases was determined using CisBio's HTRF Kinease-TK assay technology. ...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase ROS [L2026M](Homo sapiens (Human))
Array Biopharma
US Patent
Array Biopharma
US Patent
Affinity DataIC50: 3.60nMAssay Description:The potency of a compound inhibiting wild type and exemplary mutant ROS1 kinases was determined using CisBio's HTRF Kinease-TK assay technology. ...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase ROS [D2033N](Homo sapiens (Human))
Array Biopharma
US Patent
Array Biopharma
US Patent
Affinity DataIC50: 0.5nMAssay Description:The potency of a compound inhibiting wild type and exemplary mutant ROS1 kinases was determined using CisBio's HTRF Kinease-TK assay technology. ...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase ROS [L2026M](Homo sapiens (Human))
Array Biopharma
US Patent
Array Biopharma
US Patent
Affinity DataIC50: 20.4nMAssay Description:The potency of a compound inhibiting wild type and exemplary mutant ROS1 kinases was determined using CisBio's HTRF Kinease-TK assay technology. ...More data for this Ligand-Target Pair